



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: July 4, 2025.

To,

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Pharma Lifesciences Limited, Unit-1, ANVISA Audit from Brazil

This is to inform you that the Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. The audit was carried out between June 30-July 4, 2025 and has been concluded with No Critical and No Major observations. Few other observations and recommendations were discussed during the inspection, which are procedural related.

Shilpa is committed to respond to the agency through appropriate CAPA plan on the other and recommendations points within the stipulated timelines.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer